PTC Therapeutics

Yahoo Finance • 11 months ago

PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug

PTC stock rose Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy. Continue reading... Full story

Yahoo Finance • last year

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J., Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, at 7:30 a.m... Full story

Yahoo Finance • last year

Analysts on Wall Street Lower Ratings for These 10 Stocks

In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. European financial markets e... Full story

Yahoo Finance • last year

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • last year

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J., Nov. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock... Full story

Yahoo Finance • last year

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of vet... Full story

Yahoo Finance • last year

PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin

SOUTH PLAINFIELD, N.J., July 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the current therapeutic and commercial landsca... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of PTC Therapeutics, Inc. (PTCT) and Encourages Long-Term PTCT Investors to Contact the Firm

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating PTC Therapeutics, Inc. (NASDAQ: PTCT) on behalf of the company’s long-term investors. The investigation seeks to determine whether PTC ha... Full story

Yahoo Finance • 2 years ago

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. to Contact Law Firm

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties... Full story

Yahoo Finance • 2 years ago

PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding

- Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and life sciences expertise to broaden business development effort - - PTC to receive $350 million in cash at close - SOUTH PLAINFI... Full story

Yahoo Finance • 3 years ago

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

- $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected in May; ready to execute on potentia... Full story

Yahoo Finance • 3 years ago

Moore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC), Reata Pharmaceuticals, Inc. (NASDAQ: R... Full story

Yahoo Finance • 3 years ago

Moore Kuehn, PLLC Encourages Investors of PGNY, PTCT, GDOT, and RETA to Contact Law Firm

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY), PTC Therapeutics, Inc. (NASDAQ: PTCT),... Full story